HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sjölinder, M. Articles by Lindgren, J. A. Search for Related Content PubMed PubMed Citation Articles by Sjölinder, M. Articles by Lindgren, J. A. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 40, 439-446, March 1999
Copyright © 1999 by Lipid Research, Inc.

Original Article

Characterization of a leukotriene C₄ export mechanism in human platelets: possible involvement of multidrug resistance-associated protein 1

Correspondence to: Mikael Sjölinder

Platelets express leukotriene (LT) C₄ synthase and can thus participate in the formation of bioactive LTC₄. To further elucidate the relevance of this capability, we have now determined the capacity of human platelets to export LTC₄. Endogenously formed LTC₄ was efficiently released from human platelets after incubation with LTA₄ at 37°C, whereas only 15% of produced LTC₄ was exported when the cells were incubated at 0°C. The activation energy of the process was calculated to 49.9 ± 7.7 kJ/mol, indicating carrier-mediated LTC₄ export. This was also supported by the finding that the transport was saturable, reaching a maximal export rate of 470 ± 147 pmol LTC₄/min x 10⁹ platelets. Furthermore, markedly suppressed LTC₄ transport was induced by a combination of the metabolic inhibitors antimycin A and 2-deoxyglucose, suggesting energy-dependent export.

The presence in platelets of multidrug resistance-associated protein 1 (MRP1), a protein described to be an energy-dependent LTC₄ transporter in various cell types, was demonstrated at the mRNA and protein level. Additional support for a role of MRP1 in platelet LTC₄ export was obtained by the findings that the process was inhibited by probenecid and the 5-lipoxygenase-activating protein (FLAP) inhibitor, MK-886. The present findings further support the physiological relevance of platelet LTC₄ production.—Sjölinder, M., S. Tornhamre, H-E. Claesson, J. Hydman, and J. Å. Lindgren. Characterization of a leukotrine C₄ export mechanism in human platelets: possible involvement of multidrug resistance-associated protein. J. Lipid Res. 1999. 40: 439– 446.

Supplementary key words: active transport, LTA₄ metabolism, immunoblot, RT-PCR

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. van de Ven, R. Oerlemans, J. W. van der Heijden, G. L. Scheffer, T. D. de Gruijl, G. Jansen, and R. J. Scheper ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer J. Leukoc. Biol., November 1, 2009; 86(5): 1075 - 1087. [Abstract] [Full Text] [PDF]

				M. Rius, J. Hummel-Eisenbeiss, and D. Keppler ATP-Dependent Transport of Leukotrienes B4 and C4 by the Multidrug Resistance Protein ABCC4 (MRP4) J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 86 - 94. [Abstract] [Full Text] [PDF]

				K. M. Argraves and W. S. Argraves HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects J. Lipid Res., November 1, 2007; 48(11): 2325 - 2333. [Abstract] [Full Text] [PDF]

				M. Sjolinder, L. Stenke, B. Nasman-Glaser, S. Widell, J. Doucet, P.-J. Jakobsson, and J. A. Lindgren Aberrant expression of active leukotriene C4 synthase in CD16+ neutrophils from patients with chronic myeloid leukemia Blood, February 15, 2000; 95(4): 1456 - 1464. [Abstract] [Full Text] [PDF]